Energy Recovery to Release Second Quarter 2025 Financial Results
EARNINGS RELEASE
Wednesday, August 6, 2025 (after market close)
LIVE CONFERENCE CALL
Wednesday, August 6, 2025, 2 p.m. PT / 5 p.m. ET
Listen-only, US / Canada Toll-Free: +1 (888) 645-4404
Listen-only, Local / International: +1 (862) 298-0702
CONFERENCE CALL REPLAY
Expiration: September 6, 2025
US / Canada Toll-Free: +1 (877) 660-6853
Local / International Toll: +1 (201) 612-7415
Access code: 13755031
Investors may also access the live call and replay over the internet via webcast. The replay will be available approximately three hours after the live call concludes.
About Energy Recovery
Energy Recovery is a trusted global leader in energy efficiency technology. Building on our pressure exchanger technology platform, we design and manufacture reliable, high-performance solutions that generate cost savings, increase energy efficiency, and reduce carbon emissions across several industries. With a strong foundation in the desalination industry, Energy Recovery has delivered transformative solutions that increase operational efficiency and environmental sustainability to our customers worldwide for more than 30 years. Headquartered in the San Francisco Bay Area, Energy Recovery has manufacturing and R&D facilities across California, with sales and on-site technical support available globally. For more information, visit www.energyrecovery.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 minutes ago
- Business Wire
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the " Contract"). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris. On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by €60,000. Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account: - 206,211 Sensorion Ordinary Shares - €66,965.21 About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Business Insider
14 minutes ago
- Business Insider
Cantor Fitzgerald Reaffirms Their Buy Rating on Kimball Electronics (KE)
Cantor Fitzgerald analyst Derek Soderberg maintained a Buy rating on Kimball Electronics today and set a price target of $27.00. The company's shares closed today at $24.71. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Soderberg is an analyst with an average return of -0.5% and a 42.04% success rate. In addition to Cantor Fitzgerald, Kimball Electronics also received a Buy from Financial's Mike Crawford in a report issued today. However, on August 2, TR | OpenAI – 4o downgraded Kimball Electronics (NASDAQ: KE) to a Hold. The company has a one-year high of $21.52 and a one-year low of $12.41. Currently, Kimball Electronics has an average volume of 150.5K.
Business Insider
14 minutes ago
- Business Insider
NICE (NICE) Receives a Buy from Northland Securities
Northland Securities analyst Michael Latimore reiterated a Buy rating on NICE today and set a price target of $250.00. The company's shares closed today at $127.85. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Latimore covers the Technology sector, focusing on stocks such as NICE, SoundHound AI, Inc Class A, and Rekor Systems. According to TipRanks, Latimore has an average return of 7.6% and a 44.29% success rate on recommended stocks. In addition to Northland Securities, NICE also received a Buy from Rosenblatt Securities's Catharine Trebnick in a report issued today. However, on the same day, D.A. Davidson maintained a Hold rating on NICE (NASDAQ: NICE). Based on NICE's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $700.19 million and a net profit of $129.29 million. In comparison, last year the company earned a revenue of $659.31 million and had a net profit of $106.37 million
